Matches in SemOpenAlex for { <https://semopenalex.org/work/W2247138733> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- W2247138733 abstract "1006 Background: The role of adjuvant CTX in women with small BC is controversial. Here we analyze time trends of CTX use and outcomes in women with T1N0 BC treated at NCCN cancer centers. Methods: 8917 women were identified who received surgery or systemic therapy at an NCCN center with T1a, T1b or T1c N0 M0 BC between 2000-09. Tumors were grouped by biologic subgroups by hormone receptor (HR) and HER2 status and T subgroups (T1a, T1b, T1c). Primary endpoints were receipt of adjuvant CTX (± trastuzumab) and BC specific survival (BCSS). Chi-square, Cochran Armitage trend, Kaplan Meier estimates, log-rank test and Cox hazard proportional regression were used for analysis. In this report we focus on T1a/b results (N=4113). Results: Median follow up time was 5.5 years (range, 0.7-12.7). CTX use differed according to biologic and T subgroups, with significant changes over time (Table). In 2009, more than 50% of patients (pts) with HER2+ and HR-2- T1a/b breast cancers received CTX (± trastuzumab). The table lists use of CTX by year and subset and the 5 year BCSS for pts treated and not treated with CTX. Conclusions: A high proportion of pts with HER2+ and HR-HER2- T1N0 breast cancers received adjuvant CTX, with a sharp increase in use of CTX among HER2+ over the past decade. Use of CTX is higher in T1b compared to T1a tumors. In this study, women with T1a and T1b tumors have an excellent prognosis without CTX at 5 Yr. Careful examination of cutoffs for absolute benefit sufficient to recommend CTX is warranted. [Table: see text]" @default.
- W2247138733 created "2016-06-24" @default.
- W2247138733 creator A5001934879 @default.
- W2247138733 creator A5008812852 @default.
- W2247138733 creator A5010686398 @default.
- W2247138733 creator A5011567248 @default.
- W2247138733 creator A5015055171 @default.
- W2247138733 creator A5017550097 @default.
- W2247138733 creator A5019007552 @default.
- W2247138733 creator A5049174232 @default.
- W2247138733 creator A5053598597 @default.
- W2247138733 creator A5055301443 @default.
- W2247138733 creator A5073488441 @default.
- W2247138733 creator A5087846772 @default.
- W2247138733 creator A5090188675 @default.
- W2247138733 date "2013-05-20" @default.
- W2247138733 modified "2023-09-23" @default.
- W2247138733 title "Time trends in the use of adjuvant chemotherapy (CTX) and outcomes in women with T1N0 breast cancer (BC) in the National Comprehensive Cancer Network (NCCN)." @default.
- W2247138733 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.1006" @default.
- W2247138733 hasPublicationYear "2013" @default.
- W2247138733 type Work @default.
- W2247138733 sameAs 2247138733 @default.
- W2247138733 citedByCount "3" @default.
- W2247138733 countsByYear W22471387332014 @default.
- W2247138733 countsByYear W22471387332015 @default.
- W2247138733 crossrefType "journal-article" @default.
- W2247138733 hasAuthorship W2247138733A5001934879 @default.
- W2247138733 hasAuthorship W2247138733A5008812852 @default.
- W2247138733 hasAuthorship W2247138733A5010686398 @default.
- W2247138733 hasAuthorship W2247138733A5011567248 @default.
- W2247138733 hasAuthorship W2247138733A5015055171 @default.
- W2247138733 hasAuthorship W2247138733A5017550097 @default.
- W2247138733 hasAuthorship W2247138733A5019007552 @default.
- W2247138733 hasAuthorship W2247138733A5049174232 @default.
- W2247138733 hasAuthorship W2247138733A5053598597 @default.
- W2247138733 hasAuthorship W2247138733A5055301443 @default.
- W2247138733 hasAuthorship W2247138733A5073488441 @default.
- W2247138733 hasAuthorship W2247138733A5087846772 @default.
- W2247138733 hasAuthorship W2247138733A5090188675 @default.
- W2247138733 hasConcept C121608353 @default.
- W2247138733 hasConcept C126322002 @default.
- W2247138733 hasConcept C143998085 @default.
- W2247138733 hasConcept C2776694085 @default.
- W2247138733 hasConcept C2777863537 @default.
- W2247138733 hasConcept C29456083 @default.
- W2247138733 hasConcept C3018227240 @default.
- W2247138733 hasConcept C530470458 @default.
- W2247138733 hasConcept C71924100 @default.
- W2247138733 hasConceptScore W2247138733C121608353 @default.
- W2247138733 hasConceptScore W2247138733C126322002 @default.
- W2247138733 hasConceptScore W2247138733C143998085 @default.
- W2247138733 hasConceptScore W2247138733C2776694085 @default.
- W2247138733 hasConceptScore W2247138733C2777863537 @default.
- W2247138733 hasConceptScore W2247138733C29456083 @default.
- W2247138733 hasConceptScore W2247138733C3018227240 @default.
- W2247138733 hasConceptScore W2247138733C530470458 @default.
- W2247138733 hasConceptScore W2247138733C71924100 @default.
- W2247138733 hasLocation W22471387331 @default.
- W2247138733 hasOpenAccess W2247138733 @default.
- W2247138733 hasPrimaryLocation W22471387331 @default.
- W2247138733 isParatext "false" @default.
- W2247138733 isRetracted "false" @default.
- W2247138733 magId "2247138733" @default.
- W2247138733 workType "article" @default.